BioCentury
ARTICLE | Product Development

vTv’s potential first-in-class therapy heading for Phase III after clearing Type I diabetes hurdle

February 11, 2020 12:28 AM UTC

Based on the 52% bump that vTv’s shares received on Monday, investors believe new data from a Phase II trial of the company’s glucokinase activator to treat Type I diabetes could portend further success in a planned pivotal study. The company hopes the therapy, TTP399, can become a first-in-class oral adjunctive treatment to insulin for Type I diabetics.

vTv Therapeutics Inc. (NASDAQ:VTVT) said Monday that TTP399 significantly reduced HbA1c vs. placebo in the second part of the Phase II Simplici-T1 trial at week 12, meeting its primary endpoint (p=0.03). The company is seeking to show that the GCK activator helps maintain glycemic control in the adjunctive setting among adults with the disease...

BCIQ Company Profiles

vTv Therapeutics Inc.

BCIQ Target Profiles

Glucokinase (GCK) (GK)